Compounds of formula (I) wherein \( R^1 \) is hydrogen, alkyl of 1 to 6 carbon atoms, or NR\(^4\)R\(^5\) wherein R\(^4\) and R\(^5\) are independently selected from hydrogen and alkyl of 1 to 6 carbon atoms or a pharmaceutically acceptable cation; R\(^2\) is hydrogen, hydroxy, alkanoylamino of 1 to 6 carbon atoms, morpholino, halogen, hydroxyalkyl of 1 to 6 carbon atoms, CO-OR\(^6\) wherein R\(^6\) is alkyl of 1 to 6 carbon atoms or a pharmaceutically acceptable cation, alkoxyl of 1 to 6 carbon atoms, hydrogen, alkoxyl of 1 to 6 carbon atoms, aminooalkyl of 2 to 6 carbon atoms, alkylaminoalkyl wherein each alkyl group is independently selected from alkyl groups having 2 to 6 carbon atoms, and dialkylaminoalkyl wherein each alkyl group is independently selected from alkyl groups having one to six carbon atoms, with the proviso that only one of R\(^7\) and R\(^8\) may be alkoxyl; and R\(^3\) is hydrogen, alkyl of 1 to 6 carbon atoms, phenyl or substituted phenyl wherein the phenyl group may be substituted with one or two substituents selected from the group consisting of alkyl of 1 to 6 carbon atoms, nitro, amino, halogen, (e.g., fluoro, chloro, bromo, or iodo), haloalkyl of 1 or 2 carbon atoms and up to 3 halogen atoms (e.g., fluoro, chloro, bromo or iodo), hydroxyl, or alkoxyl of 1 to 6 atoms and pharmaceutically acceptable acid addition salts thereof. The compounds have antibacterial activity.
FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th>Code</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>AT</td>
<td>Austria</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
</tr>
<tr>
<td>DE</td>
<td>Germany, Federal Republic of</td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
</tr>
<tr>
<td>FI</td>
<td>Finland</td>
</tr>
<tr>
<td>FR</td>
<td>France</td>
</tr>
<tr>
<td>GA</td>
<td>Gabon</td>
</tr>
<tr>
<td>GB</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>HU</td>
<td>Hungary</td>
</tr>
<tr>
<td>IT</td>
<td>Italy</td>
</tr>
<tr>
<td>JP</td>
<td>Japan</td>
</tr>
<tr>
<td>KP</td>
<td>Democratic People's Republic</td>
</tr>
<tr>
<td>KR</td>
<td>Republic of Korea</td>
</tr>
<tr>
<td>LI</td>
<td>Liechtenstein</td>
</tr>
<tr>
<td>LK</td>
<td>Sri Lanka</td>
</tr>
<tr>
<td>LU</td>
<td>Luxembourg</td>
</tr>
<tr>
<td>MC</td>
<td>Monaco</td>
</tr>
<tr>
<td>MG</td>
<td>Madagascar</td>
</tr>
<tr>
<td>ML</td>
<td>Mali</td>
</tr>
<tr>
<td>MR</td>
<td>Mauritania</td>
</tr>
<tr>
<td>MW</td>
<td>Malawi</td>
</tr>
<tr>
<td>NL</td>
<td>Netherlands</td>
</tr>
<tr>
<td>NO</td>
<td>Norway</td>
</tr>
<tr>
<td>RO</td>
<td>Romania</td>
</tr>
<tr>
<td>SD</td>
<td>Sudan</td>
</tr>
<tr>
<td>SE</td>
<td>Sweden</td>
</tr>
<tr>
<td>SN</td>
<td>Senegal</td>
</tr>
<tr>
<td>SU</td>
<td>Soviet Union</td>
</tr>
<tr>
<td>TD</td>
<td>Chad</td>
</tr>
<tr>
<td>TG</td>
<td>Togo</td>
</tr>
<tr>
<td>US</td>
<td>United States of America</td>
</tr>
</tbody>
</table>
AZETIDINYL QUINOLONE CARBOXYLIC ACIDS AND ESTERS

Background of the Invention

This invention relates to azetidinyl quinolone carboxylic acids and esters, antibacterial compositions containing said compounds, methods of using said compounds, and methods of preparing said compounds.

United States Patent 4,563,459 refers to 1-cyclopropyl-1,4-dihydro-4-oxo-quinoline carboxylic acids wherein the moiety in the 6-position is hydrogen, fluorine, chlorine, bromine or nitro and the moiety in the 7-position is hydrogen, chlorine, fluorine or NR³R⁴ wherein R³ and R⁴ represent separate groups or, together with the nitrogen atom on which they are positioned, may form a 5-membered or 6-membered heterocyclic ring.

Japanese Kokai SHO 60-89480 refers to compounds of the formula

![Chemical Structure](image)

wherein Z is nitrogen or CH; X is halogen; R¹ and R² are hydrogen, acyl or lower alkyl; m is 1 or 2; and n is 1, 2 or 3. However, no specific quinoline compounds are disclosed.

Summary of the Invention

The present invention relates to compounds of the formula
wherein $R^1$ is hydrogen, alkyl of 1 to 6 carbon atoms, or $NR^4R^5$ wherein $R^4$ and $R^5$ are independently selected from hydrogen and alkyl of 1 to 6 carbon atoms or a pharmaceutically acceptable cation;

$R^2$ is hydrogen, hydroxy, alkanoylamino of 1 to 6 carbon atoms, morpholino, halogen, hydroxyalkyl of 1 to 6 carbon atoms, COOR$^6$ wherein $R^6$ is alkyl of 1 to 6 carbon atoms or a pharmaceutically acceptable cation, alkoxy of 1 to 6 carbon atoms, $NR^7R^8$ wherein $R^7$ and $R^8$ are independently selected from alkyl of 1 to 6 carbon atoms, alkanoyl of 1 to 6 carbon atoms, hydrogen, alkoxy of 1 to 6 carbon atoms, aminoalkyl of 2 to 6 carbon atoms, alkylaminoalkyl wherein each alkyl group is independently selected from alkyl groups having 2 to 6 carbon atoms, and dialkylaminoalkyl wherein each alkyl group is independently selected from alkyl groups having one to six carbon atoms, with the proviso that only one of $R^7$ and $R^8$ may be alkoxy; and

$R^3$ is hydrogen, alkyl of 1 to 6 carbon atoms, phenyl or substituted phenyl wherein the phenyl group may be substituted with one or two substituents selected from the group consisting of alkyl of 1 to 6 carbon atoms, nitro, amino, halogen (e.g., fluoro, chloro, bromo, or iodo), haloalkyl of 1 or 2 carbon atoms and up to 5 halogen atoms (e.g., fluoro, chloro, bromo or iodo), hydroxyl, or alkoxy of 1 to 6 atoms and pharmaceutically acceptable acid addition salts thereof. The compounds have antibacterial activity.
The present invention also relates to pharmaceuti-
cal compositions comprising a pharmaceutically accept-
able carrier or diluent and a compound of the formula I
or a pharmaceutically acceptable salt thereof in an
antibacterially effective amount. The present
invention also provides a method of treating an animal,
including a human being, having a bacterial disease
which comprises administering to the animal (e.g.,
mammal, bird or fish) an antibacterially effective
amount of a compound of the formula I or a
pharmaceutically acceptable acid addition salt thereof.
The present invention also relates to methods of
preparing the compounds of formula I.

The compounds of the invention include racemic
mixtures and optical isomers. Preferred compounds of
the invention are those of formula I wherein R^1 is
hydrogen, a pharmaceutically acceptable cation (e.g.,
sodium or potassium), or amino. Other preferred
compounds are those of formula I wherein R^2 is
hydrogen, amino, hydroxy, hydroxymethyl, acetylamino or
COOR^6, wherein R^6 is hydrogen, a pharmaceutically
acceptable cation, or amino. Other preferred compounds
are those of formula I wherein R^3 is hydrogen or
phenyl. More preferred compounds are those wherein R^1
is hydrogen, a pharmaceutically acceptable cation, or
amino; R^2 is hydrogen, amino, or hydroxy and R^3 is
hydrogen or phenyl. Specific preferred compounds are
as follows:

1-cyclopropyl-6-fluoro-1,4-dihydro-7-[1'-
azetidinyl]-4-oxo-3-quinoline-carboxylic acid;
1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3'hydroxy-
1'-azetidinyl]-4-oxo-3-quinoline-carboxylic acid;
1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3'amo-no-1'
azetidinyl]-4-oxo-3-quinoline-carboxylic acid; and
1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3'-acetyl-amino-1'-azetidinyl]-4-oxo-3-quinoline-carboxylic acid.

The pharmaceutical compositions of the present invention preferably contain the above preferred and specific preferred compounds.

Other compounds of the present invention are the following:

1-cyclopropyl-6-fluoro-1,4-dihydro-7-[2'-phenyl-3'-amino-1'-azetidinyl]-4-oxo-3-quinoline-carboxylic acid;

1-cyclopropyl-6-fluoro-1,4-dihydro-7-[2'-methyl-3'-hydroxy-1'-azetidinyl]-4-oxo-3-quinoline-carboxylic acid;

1-cyclopropyl-6-fluoro-1,4-dihydro-7-[2'-methyl-3' amino-1'-azetidinyl]-4-oxo-3-quinoline-carboxylic acid;

1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3'-carboxyl-1'-azetidinyl]-4-oxo-3-quinoline-carboxylic acid;

1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3'-cyano-1'-azetidinyl]-4-oxo-3-quinoline-carboxylic acid;

1-cyclopropyl-6-fluoro-1,4-dihydro-7-[2'-ethyl-3'-hydroxy-1'-azetidinyl]-4-oxo-3-quinoline-carboxylic acid;

1-cyclopropyl-6-fluoro-1,4-dihydro-7-[2'-propyl-3' amino-1'-azetidinyl]-4-oxo-3-quinoline-carboxylic acid;

1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3'-hydroxy methyl-1'-azetidinyl]-4-oxo-3-quinoline-carboxylic acid;

1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3'-amino methyl-1'-azetidinyl]-4-oxo-3-quinoline-carboxylic acid.
Detailed Description of the Invention

The compounds of the present invention may be prepared by reacting a quinolone of the formula

\[
\text{II} \quad \text{F} \quad \text{X} \quad \text{COOR}^1
\]

wherein \(R^1\) is as defined above and \(X\) is fluoro, chloro, bromo or iodo (preferably, fluoro or chloro; more preferably, fluoro) with an amine of the formula

\[
\text{III} \quad \text{R}^2 \quad \text{NH} \quad \text{R}^3
\]

wherein \(R^2\) and \(R^3\) are as defined above, in an inert solvent or in a basic solvent. Examples of suitable solvents are tetrahydrofuran, pyridine, ethanol, chloroform, dimethylsulfoxide, dimethylformamide, water and mixtures thereof. If the solvent is not a basic solvent such as, for example, pyridine, it is desirable to add a base to the reaction mixture. The base serves to facilitate completion of the reaction by reacting with the hydrogen fluoride that is produced in the reaction. The addition of DBU (which is a strong base) to the reaction mixture is preferred. A preferred solvent is a mixture of acetonitrile and 1,8-diazabicyclo(5.4.0) - undec-7-ene (DBU). Especially preferred, is acetonitrile solvent containing 1 to 3 equivalents of DBU. The temperature and pressure are not critical. Generally, however, a temperature of 30 to 100°C and a pressure of 0.5 to 2 atmospheres are preferred. More preferably, the pressure is ambient pressure (generally, about 1
atmosphere). Although a significant amount of product may be formed in about 5 minutes, the reaction is generally allowed to proceed overnight. The product is isolated by conventional methods. For example, the product may be isolated by adding water to the reaction mixture, adjusting the pH to 7.0-7.4, collecting the resulting precipitate by filtration and then water washing and drying the precipitate. Using conventional methods, compounds of the present invention wherein $R_1$ is other than hydrogen may be prepared by converting a compound of the formula I wherein $R_1$ is hydrogen to the corresponding ester or amide. Alternatively, a compound of the formula II wherein $R_1$ is hydrogen may be converted to the corresponding ester or amide by conventional methods and that ester or amide may then be used to prepare a compound of the formula I as described above.

Compounds of the formula II may be prepared as described in United States Patent 4,563,459.

Amines or alcohols of the formula III may be prepared by well known methods. See, for example, T. Okutani et al., Chem. Pharm. Bull., 22, 1490-1497 (1974); S. Chatterjee et al., Chem. Comm., 93 (1968); D. Nisato et al., J. Heterocyclic Chem., 22, 961 (1985); I. Hayakawa et al., Chem. Pharm. Bull., 32, 4907-4913 (1984); A.G. Anderson et al., J. Org. Chem., 37, 3953-3955 (1972); and V.R. Gaertner, J. Org. Chem., 32, 2972-2976 (1967). Thus, for example 2-phenyl and 2-substituted phenyl-3-amino-azetidines may be prepared by the method of T. Okutani et al. and 3-hydromethyl-1-azetidine may be prepared by the method of I. Hayakawa et al.

The pharmaceutically acceptable acid addition salts of the compounds of the formula I are prepared in
a conventional manner by treating a solution or suspension of the free base of the formula I with about one chemical equivalent of a pharmaceutically acceptable acid. Conventional concentration and recrystallization techniques are employed in isolating the salts. Illustrative of suitable acids are acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, methanesulfonic, cinnamic, fumaric, phosphonic, hydrochloric, hydrobromic, hydroiodic, sulfamic and sulfonic acid.

The pharmaceutically acceptable cationic salts of formula I may be prepared by conventional methods from the corresponding acids, e.g., by reaction with about one equimolar amount of a base. Examples of suitable cationic salts are those of alkali metals such as sodium or potassium, alkaline earth metals such as magnesium or calcium, and ammonium or organic amines such as diethanol amine or N-methyl-glucamine.

The compounds of formula I and the pharmaceutically acceptable acid addition salts thereof are broad spectrum antibacterials useful in the treatment of bacterial infections, particularly the treatment of infections of gram-positive bacterial strains.

The compounds of the present invention may be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For example, they can be administered orally or in the form of tablets containing such excipients as starch or lactose, or in capsules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents. In the case of animals
(for example, swine, cattle, horses, and poultry), they are advantageously contained in an animal feed or drinking water in a concentration of about 5 to about 5000 ppm, preferably about 25 to about 500 ppm. They can be injected parenterally, for example, intramuscularly, intravenously or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous solution which can contain other solutes, for example, enough salt or glucose to make the solution isotonic. In the case of animals, compounds can be administered intramuscularly or subcutaneously at dosage levels of about 0.1 to about 50 mg/kg/day, advantageously about 0.2 to about 10 mg/kg/day, given in a single daily dose or up to 3 divided doses.

The invention also provides pharmaceutical compositions comprising an antibacterially effective amount of a compound of the formula I or a pharmaceutically acceptable acid addition salt thereof together with a pharmaceutically acceptable diluent or carrier.

The compounds of the present invention can be administered to humans for the treatment of bacterial diseases by either the oral or parenteral routes, and may be administered orally at dosage levels of about 0.1 to about 500 mg/kg/day, advantageously about 0.5 to about 50 mg/kg/day, given in a single dose or up to 3 divided doses. For intramuscular or intravenous administration, dosage levels are about 0.1 to about 200 mg/kg/day, advantageously about 0.5 to about 50 mg/kg/day. Intramuscular administration may be accomplished with a single dose or up to 3 divided
doses. Intravenous administration may be accomplished with a continuous drip. Variations will necessarily occur depending on the weight and condition of the subject being treated and the particular route of administration chosen as will be known to those skilled in the art.

The antibacterial activity of the compounds of the invention is shown by testing according to the Steer's replicator technique which is a standard in vitro bacterial testing method described by E. Steers et al., Antibiotics and Chemotherapy, 9, 307 (1959).

The following non-limiting Examples illustrate the invention. All melting points referred to in the Examples are uncorrected.

**Example 1**

1-cyclopropyl-6-fluoro-1,4-dihydro-7-[[1'-azetidinyl]-4-oxo-3-quinoline-carboxylic acid

A mixture of 1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (1.591 g, 6 mmole), acetonitrile (70 ml), azetidine (390 mg, 6.8 mmole) and DBU (913 mg, 6 mmole) were heated at reflux. After only 5 minutes of heating, it was observed that crystalline material was precipitating. After 5 additional minutes of heating, the hot solution was filtered. The reaction mixture was then allowed to cool at room temperature for 1 hour. The solid material that precipitated was collected by filtration, washed first with acetonitrile and then with ethyl ether and then dried to give 650 mg of the title compound, m.p. 298-299°C (dec.). NMR (DMSO-D6): 1.12-1.13 d and 1.26-1.28 d, 4H of cyclopropane; 2.3-2.4, m, 2H of C3' azetidine; 3.2-3.7, q, 1H of cyclopropane; 4.19-4.24, q, 4H of azetidine C2' and C4'; 6.82-6.85, d, 1H of C8; 7.74-7.78, d, 1H of C5; 8.55, s, 1H of C2.
A second crop of crystals was obtained and was washed and dried as described above to give 210 mg of the title compound, m.p. 297-299°C (dec.). The combined yield was 48%.

Example 2
1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3'-amino-1'-azetidinyl]-4-oxo-3-quinoline-carboxylic acid and its hydrochloride salt

A mixture of 3-amino-1-azetidine (80 mg, 0.048 mmole), 1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (10.6 mg, 0.04 mole) and DBU (0.0113 ml, 12.1 mg, 0.08 mmole) in 5 ml of acetonitrile was refluxed under nitrogen (79-80°C) for 3 hours and was then allowed to stand at room temperature under nitrogen overnight. The reaction mixture was then filtered and the wet cake was washed with acetonitrile and then with ethyl ether. The cake was then dried in vacuo to give 15 mg of the title compound, m.p. 277-278°C.

The hydrochloride salt of the title compound was prepared by adding 130 mg (0.04 mmole) of the title compound to methanolic HCl containing an equivalent amount (0.04 mmole) of HCl and stirring at room temperature for 4 hours. Crystals were collected by filtration, washed with ethyl ether and dried to give 22.3 mg of the hydrochloride salt, m.p. above 300°C.

NMR (DMSO-D6): 1.12-1.13, d, and 1.26-1.28 d, 4H of cyclopropane, 3.8, s, 1H of cyclopropane; 4.05-4.25, m, 4H of C₂' and C₄' azetidine; 4.46-4.52, q, 1H of azetidine C₃'; 6.92-6.98, d, 1H of C₈; 7.80-7.86, d, 1H of C₅; 8.6, s, 1H of C₂; 8.68-8.84, d, 2H of NH₂.
Example 3

1-Cylopropyl-6-fluoro-1,4-dihydro-7-[3'-hydroxy-1'-azetidinyl]-4-oxo-3-quinoline-carboxylic acid

A mixture of 3-hydroxy-1-azetidine hydrochloride (120 mg, 1.1 mmole), 1-cylopropyl-6,7-difluoro 1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (265 mg, 1 mmole) and 299 ml (2 mmole) of DBU in 10 ml of acetonitrile was refluxed under nitrogen for 2.5 hours and was then filtered hot. The wet cake was washed with acetonitrile and dried to give 130 mg of the title compound, m.p. 294-295°C (dec.).

Example 4

1-Cylopropyl-6-fluoro-1,4-dihydro-7-[3'-carboxyl-1'-azetidinyl]-4-oxo-3-quinoline-carboxylic acid and its 3'-sodium carboxylate

A mixture of 1-cylopropyl-6,7-difluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (132.5 mg, 0.005 mmole), azetidine-3-carboxylic acid (55.6 mg, 0.055 mmole) and DBU (0.075 ml, 0.05 mmole) in 5 ml of acetonitrile was refluxed under nitrogen for 2 hours. The reaction mixture was then allowed to cool at room temperature for 2 hours. The resulting solid was suspended in 3 ml of water and the pH was adjusted to 8.5 by the addition of saturated aqueous NaHCO₃ solution. Ethyl ether was then added. The resulting mixture was shaken in a separatory funnel and the organic layer was separated. The aqueous layer was filtered and the filtered solution was freeze dried overnight to yield 180 mg (92%) of the title compound as the disodium salt, m.p. 287-289°C (dec.).
Example 5

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-[3'-acetylamino-1'-azetidinyl]-4-oxo-3-quinoline-carboxylic acid and its hydrochloride salt

A mixture of 3-acetylamino-1-azetidine (110 mg, 0.963 mmole), 1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (212 mg, 0.8 mmole) and DBU (0.134 ml, 137 mg, 0.9 mmole) in 10 ml of acetonitrile were refluxed under nitrogen (79-80°C) for one hour and was then allowed to stand at room temperature under nitrogen overnight. The reaction mixture was then filtered and the wet cake was washed with acetonitrile and then with ethyl ether. The cake was then dried in vacuo to give 311 mg of the title compound.

The hydrochloride salt was prepared by adding the title compound (100 mg) to methanolic HCl containing an equivalent amount of HCl and stirring at room temperature for 30 minutes. The solid material that formed was filtered, washed with acetonitrile, and dried in vacuo to give 83.7 mg (76%) of the hydrochloride salt, m.p. 265-266°C dec.

Example 6

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-[2'-methyl-3'-hydroxy-1'-azetidinyl]-4-oxo-3-quinoline-carboxylic acid

Following the method of Example 1, but employing 2-methyl-3-hydroxy-1-azetidine in place of azetidine, there was obtained the title compound, m.p. above 300°C.
Example 7
1-Cyclopropyl-6-fluoro-1,4-dihydro-7-[3'-hydroxy-methyl-1'-azetidinyl]-4-oxo-3-quinoline-carboxylic acid

A mixture of 3-hydroxymethyl-1-azetidine 4.4 mg, 0.05 mmole), 1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (10.6 mg, 0.04 mmole) and DBU (0.0113 ml, 12.1 mg, 0.08 mmole) in 5 ml of acetonitrile was refluxed under nitrogen for 3 hours and was then allowed to stand at room temperature under nitrogen overnight. The reaction mixture was then filtered, and the wet cake was washed with acetonitrile and dried in vacuo to give 9.9 mg (59%) of the title compound, m.p. about 300°C.

Example 8
1-Cyclopropyl-6-fluoro-1,4-dihydro-7-[2'-phenyl-3'-amino-1'-azetidinyl]-4-oxo-3-quinoline carboxylic acid

2-phenyl-3-amino-1-azetidine dihydrochloride (9.24 mg, 0.05 mmole), 1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (10.6 mg, 0.04 mmole) and DBU (12.1 mg, 0.08 mmole) in 5 ml of acetonitrile was refluxed for 8 hours and then allowed to stand at room temperature overnight under nitrogen. The mixture was then filtered, washed with acetonitrile and dried in vacuo to give 6.3 mg (40%), m.p. above 300°C.

Example 9
The title compounds of Examples 1, 2, 3 and 5 were tested for in vitro antibacterial activity using the Steer's replicator technique. The compounds were found to be active against Staphylococcus aureus, Staphylococcus epidermis, Streptococcus pyogenes, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pasteurella multocida, Serratia marcescens, Neisseria sicca, Enterobacter aerogenes, Enterobacter cloacae, and Morganella morganii at levels lower than 3.2 micrograms per ml.
CLAIMS

1. A compound of the formula

\[
\text{COOR}^1
\]

wherein \( R^1 \) is hydrogen, alkyl of 1 to 6 carbon atoms, or \( NR^4 R^5 \), wherein \( R^4 \) and \( R^5 \) are independently selected from hydrogen and alkyl of 1 to 6 carbon atoms or a pharmaceutically acceptable cation;

\( R^2 \) is hydrogen, hydroxy, alkanoylamino of 1 to 6 carbon atoms, morpholino, halogen, hydroxyalkyl of 1 to 6 carbon atoms, \( \text{COOR}^6 \) wherein \( R^6 \) is alkyl of 1 to 6 carbon atoms or a pharmaceutically acceptable cation, alkoxy of 1 to 6 carbon atoms, \( NR^7 R^8 \) wherein \( R^7 \) and \( R^8 \) are independently selected from alkyl of 1 to 6 carbon atoms, alkanoyl of 1 to 6 carbon atoms, hydrogen, alkoxy of 1 to 6 carbon atoms, aminoalkyl of 2 to 6 carbon atoms, alkylaminoalkyl wherein each alkyl group is independently selected from alkyl groups having 2 to 6 carbon atoms, and dialkylaminoalkyl wherein each alkyl group is independently selected from alkyl groups having one to six carbon atoms, with the proviso that only one of \( R^7 \) and \( R^8 \) may be alkoxy; and

\( R^3 \) is hydrogen, alkyl of 1 to 6 carbon atoms, phenyl or substituted phenyl wherein the phenyl group may be substituted with one or two substituents
selected from the group consisting of alkyl of 1 to 6 carbon atoms, nitro, amino, halogen, haloalkyl of 1 or 2 carbon atoms and up to 5 halogen atoms, hydroxy, or alkoxy of 1 to 6 atoms and pharmaceutically acceptable acid addition salts thereof.

2. A compound according to claim 1, wherein R² is hydrogen, amino, hydroxy, acetylamino, hydroxymethyl, or COOR⁶ wherein R⁶ is hydrogen, a pharmaceutically acceptable cation or amino.

3. A compound according to claim 1, wherein R¹ is hydrogen, a pharmaceutically acceptable cation or amino.

4. A compound according to claim 1, wherein R¹ is an alkali metal or alkaline earth metal cation.

5. A compound according to claim 1, wherein R⁶ is an alkali metal or alkaline earth metal cation.

6. A compound according to claim 1 wherein R² is hydrogen, amino or hydroxy and R³ is hydrogen or phenyl.

7. A compound according to claim 6 wherein R¹ is hydrogen, a pharmaceutically acceptable cation or amino.

8. A compound according to claim 1, said compound being selected from the group consisting of

1-cyclopropyl-6-fluoro-1,4-dihydro-7-[1'-azetidinyl]-4-oxo-3-quinolinecarboxylic acid;

1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3'-hydroxy-1'-azetidinyl]-4-oxo-3-quinolinecarboxylic acid;

1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3'-amino-1'-azetidinyl]-4-oxo-3-quinolinecarboxylic acid;
1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3'-acetyl-amino-1'-azetidinyl]-4-oxo-3-quinolinecarboxylic acid;
1-cyclopropyl-6-fluoro-1,4-dihydro-7-[2'-methyl-3'-amino-1'-azetidinyl]-4-oxo-3-quinolinecarboxylic acid;
1-cyclopropyl-6-fluoro-1,4-dihydro-7-[2'-phenyl-3'-amino-1'-azetidinyl]-4-oxo-3-quinolinecarboxylic acid; and pharmaceutically acceptable acid addition salts of the foregoing compounds.

9. An antibacterial composition comprising a compound according to claim 1 in an amount sufficient for treatment of a bacterial infection, and a pharmaceutically acceptable carrier.

10. A composition according to claim 9, wherein \( R^2 \) is hydrogen, amino, hydroxy, acetylamino, hydroxymethyl, \( \text{COOR}^6 \), wherein \( R^6 \) is hydrogen a pharmaceutically acceptable cation, or amino.

11. A composition according to claim 10, wherein \( R^1 \) is hydrogen, a pharmaceutically acceptable cation or amino.

12. A composition according to claim 9, wherein \( R^1 \) is an alkali metal or alkaline earth metal cation.

13. A composition according to claim 9, wherein \( R^6 \) is an alkali metal or alkaline earth metal cation.

14. A composition according to claim 9, wherein \( R^2 \) is hydrogen, amino or hydroxy and \( R^3 \) is hydrogen or phenyl.

15. A composition according to claim 14, wherein \( R^1 \) is hydrogen, a pharmaceutically acceptable cation or amino.

16. A method for the treatment of bacterial infection which comprises administering to a subject in need of treatment an antibacterially effective amount of a compound according to claim 1.
17. A method according claim 16, wherein \( R^2 \) is hydrogen, amino, hydroxy, acetylamino, hydroxymethyl, or COOR\(^6 \) wherein \( R^6 \) is hydrogen, a pharmaceutically acceptable cation, or amino.

18. A method according to claim 16, wherein \( R^1 \) is hydrogen, a pharmaceutically acceptable cation or amino.

19. A method according to claim 16, wherein \( R^2 \) is hydrogen, amino or hydroxy and \( R^3 \) is hydrogen or phenyl.

20. A method according to claim 19, wherein \( R^1 \) is hydrogen, a pharmaceutically acceptable cation or amino.
## INTERNATIONAL SEARCH REPORT

### I. CLASSIFICATION OF SUBJECT MATTER

According to International Patent Classification (IPC) or to both National Classification and IPC:

**IPC(4):** C07D 401/04; 413/14; A61K 31/47; 31/535  
**US CL:** 514/236, 312; 544/128; 546/156

### II. FIELDS SEARCHED

<table>
<thead>
<tr>
<th>Classification System</th>
<th>Classification Symbols</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>514/236, 312; 544/128; 546/156</td>
</tr>
<tr>
<td>IPC</td>
<td>A61K 31/47, 31/535</td>
</tr>
</tbody>
</table>

**Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched**

**CAS ONLINE SEARCH: 1967-12/14/87 FOR QUINOLINE DERIVATIVES**

### III. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of Document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to Claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>US, A, 4,623,650 (GILLIGAN) 18 November 1986, See Claims 1, 9 and 13.</td>
<td>1-20</td>
</tr>
<tr>
<td>Y</td>
<td>US, A, 4,665,079 (CULBERTSON) 12 May 1987, See Column 2, lines 9-68; Column 3, lines 1-33; Column 28, lines 7-31; Column 41, lines 47-67.</td>
<td>1-20</td>
</tr>
<tr>
<td>Y</td>
<td>US, A, 4,670,444 (GROHE) 2 June 1987, See Claims 1, 16 and 19.</td>
<td>1-20</td>
</tr>
<tr>
<td>Y</td>
<td>EP, B, 131,839 (CHU) 23 January 1985, See page 1, lines 30-34; page 2, lines 1-4; page 4, lines 5-34; pages 35 and 36, Table III, examples 10, 14 and 16.</td>
<td>1-20</td>
</tr>
<tr>
<td>Y</td>
<td>JP, B, 62-469 (DANIPPON PHARM) 6 January 1987, See Page 599.</td>
<td>1-20</td>
</tr>
</tbody>
</table>

* Special categories of cited documents:
  * “A” document defining the general state of the art which is not considered to be of particular relevance.
  * “E” earlier document but published on or after the international filing date.
  * “L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified).
  * “O” document referring to an oral disclosure, use, exhibition or other means.
  * “P” document published prior to the international filing date but later than the priority date claimed.
  * “T” later document published after the international filing date of priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention.
  * “X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step.
  * “Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
  * “Z” document member of the same patent family.

### IV. CERTIFICATION

Date of the Actual Completion of the International Search:

16 December 1987

Date of Mailing of this International Search Report:

21 January 1988

International Searching Authority:

ISA/US

Signature of Authorized Officer:

Emily Bernhardt

Emily Bernhardt

Form PCT/ISA/210 (second sheet) (May 1986)
### III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of Document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to Claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>JP, B, 60-89480 (DANIPPON PHARM) 20 May 1985, See page 837, column 1.</td>
<td>1-20</td>
</tr>
</tbody>
</table>